DyAnsys

The neurostimulation device, which is currently for investigational use only, aims to treat cognitive and functional decline in Alzheimer's patients.

  The company’s device, Primary Relief, is the latest of DyAnsys’ long list of devices to receive FDA clearance.  

Interest in digital health is now sprouting up all over DC, from the president’s announcement of a new AI task force to FDA Commissioner’s shout out to digital health in his budget request.

DyAnsys, a medical device company specializing in the autonomic nervous system, announced this week that it has received FDA approval for a wearable auricular neurostimulation device designed to treat symptoms of opioid withdrawal.